Mark Lackner
Vermögen: 779 260 $ am 31.08.2026
Vermögen: 779 260 $ am 31.08.2026
Mark Lackner worked at Genentech, Inc. from 2012 to 2018, serving as Director from 2015 to 2018.
From 2018 to 2022, worked at IDEAYA Biosciences, Inc. as SVP, Head-Biology & Translational Sciences.
From 2022 to 2025, worked at Zentalis Pharmaceuticals, Inc. as Chief Scientific Officer from 2023 to 2025.
Education includes a doctorate from Stanford University conferred in 1997, an undergraduate degree from the University of Illinois At Urbana–Champaign in 1990, and a graduate degree from the same institution in 1991.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.04.2026 | 207’250 ( 0.22% ) | 779 260 $ | 31.08.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2025 |
| IDEAYA BIOSCIENCES, INC. | Corporate Officer/Principal | 01.10.2022 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Direktor/Vorstandsmitglied | 01.05.2018 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as oncology-focused precision medicine company which develops and sells cancer therapeutics | Health Technology |
University of Illinois At Urbana–Champaign
University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen